Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany
Mainz Biomed NV, a molecular genetics diagnostic company specializing in the early detection of cancer, announced that three German-based companies have selected ColoAlert®, the Company’s highly efficacious and easy-to-use screening test for colorectal cancer into their respective corporate health programs.
